In a clinical trial on B-ALL patients with post-CAR relapse, Sotillo et al. (1) observed that CD19 gene deletion, frameshift and exon 2 mutations in patient tumor cell samples resulted in the loss of CD19. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.